Abstract
Objectives:
To determine the effect of 5-aza-2'-deoxycytidine (DAC) on human endometrial carcinoma cell (HECC) oncogenicity and demonstrate a molecular mechanism by which DAC modulates HECC oncogenicity.
Methods:
The effect of DAC was tested on HECC RL95-2, AN3, Ishikawa and ECC1 cells. The role of 14-3-3σ on HECC oncogenicity in response to DAC treatment was evaluated in RL95-2 and AN3 cells after forced expression or silencing of 14-3-3σ gene expression.
Results:
Treatment of HECC with DAC produced non-cytotoxic cell growth inhibition and G2/M cell cycle arrest. This effect was strongly correlated with increased expression of p21 and 14-3-3σ. Silencing of 14-3-3σ induced cellular proliferation and reduced the effect of DAC on cell cycle arrest in G2/M phases. Conversely, forced expression of 14-3-3σ showed the opposite effect. Furthermore, forced expression of 14-3-3σ in human endometrial cell lines reduced cell growth and colony formation.
Conclusions:
We suggest that 14-3-3σ in HECC suppresses cell proliferation and mediates DAC induced G2/M arrest and inhibition of cell proliferation in HECC.
Copyright © 2012 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
14-3-3 Proteins / biosynthesis
-
14-3-3 Proteins / deficiency
-
14-3-3 Proteins / genetics*
-
14-3-3 Proteins / metabolism*
-
Azacitidine / analogs & derivatives*
-
Azacitidine / pharmacology
-
Biomarkers, Tumor / biosynthesis
-
Biomarkers, Tumor / deficiency
-
Biomarkers, Tumor / genetics*
-
Biomarkers, Tumor / metabolism*
-
Cell Growth Processes / drug effects
-
Cell Growth Processes / genetics
-
Cell Line, Tumor
-
Cell Survival / drug effects
-
Cell Survival / genetics
-
DNA Methylation / drug effects
-
Decitabine
-
Endometrial Neoplasms / drug therapy
-
Endometrial Neoplasms / genetics*
-
Endometrial Neoplasms / metabolism
-
Endometrial Neoplasms / pathology*
-
Exonucleases / biosynthesis
-
Exonucleases / deficiency
-
Exonucleases / genetics*
-
Exonucleases / metabolism*
-
Exoribonucleases
-
Female
-
G2 Phase Cell Cycle Checkpoints / drug effects*
-
G2 Phase Cell Cycle Checkpoints / genetics
-
Genes, Tumor Suppressor / drug effects
-
Humans
-
M Phase Cell Cycle Checkpoints / drug effects*
-
M Phase Cell Cycle Checkpoints / genetics
-
Transfection
Substances
-
14-3-3 Proteins
-
Biomarkers, Tumor
-
Decitabine
-
Exonucleases
-
Exoribonucleases
-
SFN protein, human
-
Azacitidine